766 results on '"Calo’, Girolamo"'
Search Results
2. In vitro pharmacological characterization of growth hormone secretagogue receptor ligands using the dynamic mass redistribution and calcium mobilization assays
3. Nociceptin/Orphanin FQ receptor expression in primary human umbilical vein endothelial cells is not regulated by exposure to breast cancer cell media or angiogenic stimuli
4. Neuropeptide S Encodes Stimulus Salience in the Paraventricular Thalamus
5. The NOP antagonist BTRX-246040 increases stress resilience in mice without affecting adult neurogenesis in the hippocampus
6. In vitro and in vivo pharmaco-dynamic study of the novel fentanyl derivatives: Acrylfentanyl, Ocfentanyl and Furanylfentanyl
7. In vitro and in vivo study of butyrylfentanyl and 4‐fluorobutyrylfentanyl in female and male mice: Role of the CRF1 receptor in cardiorespiratory impairment.
8. Fluorescent opioid receptor ligands as tools to study opioid receptor function
9. Pharmacological characterization of naloxegol: In vitro and in vivo studies
10. Nociceptin/orphanin FQ receptor system blockade as an innovative strategy for increasing resilience to stress
11. Pharmacological Assays for Investigating the NOP Receptor
12. NOP-Targeted Peptide Ligands
13. Nociceptin/Orphanin FQ and Urinary Bladder
14. Blockade of nociceptin/orphanin FQ signaling facilitates an active copying strategy due to acute and repeated stressful stimuli in mice
15. Plant-derived peptides rubiscolin-6, soymorphin-6 and their c-terminal amide derivatives: Pharmacokinetic properties and biological activity
16. Synthesis, biological evaluation and docking studies of a novel class of sulfur-bridged diazabicyclo[3.3.1]nonanes
17. Effects of non-peptide nociceptin/orphanin FQ receptor ligands on methylphenidate-induced hyperactivity in mice: Implications for bipolar disorders
18. Modulation of Drosophila suzukii type 1 tyramine receptor (DsTAR1) by monoterpenes: a potential new target for next generation biopesticides
19. Blockade of NOP receptor modulates anxiety-related behaviors in mice exposed to inescapable stress
20. Dopamine D1 and D2 receptors mediate neuropeptide S-induced antinociception in the mouse formalin test
21. NOP agonist action of cebranopadol counteracts its liability to promote physical dependence
22. Nociceptin/orphanin FQ receptor agonists increase aggressiveness in the mouse resident-intruder test
23. In vitro and in vivo activity of cyclopeptide Dmt-c[d-Lys-Phe-Asp]NH2, a mu opioid receptor agonist biased toward β-arrestin
24. Involvement of the N/OFQ-NOP system in rat morphine antinociceptive tolerance: Are astrocytes the crossroad?
25. Cyclopeptide Dmt-[D-Lys-p-CF3-Phe-Phe-Asp]NH2, a novel G protein-biased agonist of the mu opioid receptor
26. Peptide welding technology – A simple strategy for generating innovative ligands for G protein coupled receptors
27. Corrigendum to “Involvement of the N/OFQ-NOP system in rat morphine antinociceptive tolerance: are astrocytes the crossroad?” [Eur. J. Pharmacol. 823 (2018) 79–86]
28. Activation of nociceptin/orphanin FQ receptors inhibits contextual fear memory reconsolidation
29. Synthesis and activity of opioid peptidomimetics with β2- and β3-amino acids
30. Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt1]N/OFQ(1-13)
31. Central noradrenergic activity affects analgesic effect of Neuropeptide S
32. NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine
33. Corrigendum to “Cyclopeptide Dmt-[D-Lys-p-CF3-Phe-Phe-Asp]NH2, a novel G protein-biased agonist of the mu opioid receptor” [Peptides 101 (2018) 227–233]
34. In vitro sepsis up‐regulates Nociceptin/Orphanin FQ receptor expression and function on human T‐ but not B‐cells
35. In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations
36. Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease
37. Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems
38. Synthesis, biological evaluation and structural analysis of novel peripherally active morphiceptin analogs
39. Synthesis of mixed MOR/KOR efficacy cyclic opioid peptide analogs with antinociceptive activity after systemic administration
40. Neuropeptide S-initiated sequential cascade mediated by OX1, NK1, mGlu5 and CB1 receptors: a pivotal role in stress-induced analgesia
41. The Concise Guide to PHARMACOLOGY 2023/24 : G protein-coupled receptors
42. Functional selectivity of EM-2 analogs at the mu-opioid receptor
43. The Importance of Ligand-Receptor Conformational Pairs in Stabilization: Spotlight on the N/OFQ G Protein-Coupled Receptor
44. Intrathecal administration of nociceptin/orphanin FQ receptor agonists in rats: A strategy to relieve chemotherapy-induced neuropathic hypersensitivity
45. Blockade of nociceptin/orphanin FQ receptor signaling reverses LPS-induced depressive-like behavior in mice
46. In vitro and in vivo pharmacological characterization of Pronetupitant, a prodrug of the neurokinin 1 receptor antagonist Netupitant
47. Acute and subchronic antinociceptive effects of nociceptin/orphanin FQ receptor agonists infused by intrathecal route in rats
48. Structure activity studies of nociceptin/orphanin FQ(1–13)-NH2 derivatives modified in position 5
49. Nociceptin/orphanin FQ and stress regulate synaptophysin expression in the rat fundic and colonic mucosa
50. Central adenosine A1 and A2A receptors mediate the antinociceptive effects of neuropeptide S in the mouse formalin test
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.